First-in-class Panx1 blockers designed to address the biology that drives pain persistence.
What we do
A focused strategy built on upstream Panx1 biology with broader platform potential.
First-in-Class Panx1 Blockers
Developing Panx1 channel blockers to disrupt upstream biology at the root of neuropathic pain.
Upstream Biology Targeted
Targeting upstream drivers of pain to address the source, not just symptoms.
Non-Opioid Approach
Pursuing a non-opioid strategy for patients with chronic neuropathic pain.
Broad Platform Opportunity
Building a platform with multiple programs across indications and disease areas.
Scalable & Differentiated
Built to deliver differentiated clinical candidates and expand into multiple disease areas.